MedTrace Logo

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

NCT04564703 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-02-25

No results posted yet for this study

Summary

This is a phase II study to evaluate the efficacy and safety of different doses of iberdomide continuous therapy as maintenancetreatment after transplant.

Conditions

Interventions

DRUG

Iberdomide

IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Sponsors & Collaborators

  • Healt Data Specialists - HeaDS (CRO)

    collaborator UNKNOWN

  • EMN Research Italy Impresa Sociale Srl

    collaborator UNKNOWN

  • Stichting European Myeloma Network

    lead NETWORK

Principal Investigators

  • Francesca Gay, MD · University of Torino, Via Nizza 52, 10126 Torino

  • Niels van De Donk, MD · Amsterdam UMC, VU University Medical Center, De Boelelaan 1117, Amsterdam

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-22
Primary Completion
2023-07-27
Completion
2027-12-31

Countries

  • France
  • Greece
  • Italy
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04564703 on ClinicalTrials.gov